Search
Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
Nov 7
SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa
He describes how this dual T-cell agonist is designed to cause the expansion and reprogramming of TIL's in the body. Plus, an update on...
Nov 9, 2024
Marengo Therapeutics' CEO Zhen Su on the expansion of a partnership with Ipsen to activate T-cells against cold tumors
After announcing a partnership expansion with Ipsen on Friday, Zhen Su describes how to succeed against cold tumors where T-cells are not...
Jun 11, 2024
The CEO of Marengo Therapeutics talks about his company's focus on activating and expanding T-cells
Zen Su gives an overview Marengo, his view of #SITC23, and SITC's new biotech initiative.
Nov 4, 2023
.png){kind=logo}
